Ajeet Gajra1, Heidi D Klepin2, Tao Feng3, William P Tew4, Supriya G Mohile5, Cynthia Owusu6, Cary P Gross7, Stuart M Lichtman4, Tanya M Wildes8, Andrew E Chapman9, Efrat Dotan10, Vani Katheria3, Laura Zavala3, Chie Akiba3, Arti Hurria11. 1. Upstate Medical University and VA Medical Center, Syracuse, NY, USA. Electronic address: gajraa@upstate.edu. 2. Wake Forest School of Medicine, Winston-Salem, NC, USA. 3. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 5. University of Rochester, Rochester, NY, USA. 6. Case Western Reserve University, Cleveland, OH,USA. 7. Cancer Outcomes, Public Policy, and Effective Research Center (COPPER), Yale School of Medicine, New Haven, CT, USA. 8. Washington University School of Medicine, St Louis, MO, USA. 9. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. 10. Fox Chase Cancer Center, Philadelphia, PA, USA. 11. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: ahurria@coh.org.
Abstract
PURPOSE: Age-based reduction of chemotherapy dose with the first cycle (primary dose reduction, PDR) is not routinely guideline recommended. Few studies, however, have evaluated how frequently PDR is utilized in the treatment of older patients with cancer and which factors may be associated with this decision. METHODS: We conducted a secondary analysis of a multi-institutional prospective cohort study of patients age ≥65 years treated with chemotherapy. The dose and regimen were at the discretion of the treating oncologist. The prevalence of PDR and its association with treatment intent (palliative vs. curative), tumor type, patient characteristics (sociodemographics and geriatric assessment variables), and chemotherapy-associated toxicity were evaluated. RESULTS: Among 500 patients (mean age 73, range 65-91 years), 179 patients received curative intent chemotherapy and 321 patients received palliative intent chemotherapy, with PDR being more common in the latter sub-group (15% vs. 25%, p = 0.005). Increasing age was independently associated with PDR in both sub-groups. Comorbidity (prior cancer or liver/kidney disease) was independently associated with PDR in the palliative sub-group alone while Karnofsky Performance Status (KPS) was not associated with PDR in either subgroup. There was no significant difference in the rates of grades 3-5 toxicity, dose reductions, or delays with PDR. Patients in the palliative sub-group treated with PDR had higher rates of hospitalization compared to those treated with standard doses. CONCLUSION: PDR is more common in the palliative setting, but is also utilized among patients treated with curative intent. Factors associated with PDR include age and comorbid conditions, but not KPS. Published by Elsevier Ltd.
PURPOSE: Age-based reduction of chemotherapy dose with the first cycle (primary dose reduction, PDR) is not routinely guideline recommended. Few studies, however, have evaluated how frequently PDR is utilized in the treatment of older patients with cancer and which factors may be associated with this decision. METHODS: We conducted a secondary analysis of a multi-institutional prospective cohort study of patients age ≥65 years treated with chemotherapy. The dose and regimen were at the discretion of the treating oncologist. The prevalence of PDR and its association with treatment intent (palliative vs. curative), tumor type, patient characteristics (sociodemographics and geriatric assessment variables), and chemotherapy-associated toxicity were evaluated. RESULTS: Among 500 patients (mean age 73, range 65-91 years), 179 patients received curative intent chemotherapy and 321 patients received palliative intent chemotherapy, with PDR being more common in the latter sub-group (15% vs. 25%, p = 0.005). Increasing age was independently associated with PDR in both sub-groups. Comorbidity (prior cancer or liver/kidney disease) was independently associated with PDR in the palliative sub-group alone while Karnofsky Performance Status (KPS) was not associated with PDR in either subgroup. There was no significant difference in the rates of grades 3-5 toxicity, dose reductions, or delays with PDR. Patients in the palliative sub-group treated with PDR had higher rates of hospitalization compared to those treated with standard doses. CONCLUSION:PDR is more common in the palliative setting, but is also utilized among patients treated with curative intent. Factors associated with PDR include age and comorbid conditions, but not KPS. Published by Elsevier Ltd.
Authors: D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini Journal: N Engl J Med Date: 2001-10-11 Impact factor: 91.245
Authors: Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: Paolo Maione; Francesco Perrone; Ciro Gallo; Luigi Manzione; FrancoVito Piantedosi; Santi Barbera; Silvio Cigolari; Francesco Rosetti; Elena Piazza; Sergio Federico Robbiati; Oscar Bertetto; Silvia Novello; Maria Rita Migliorino; Adolfo Favaretto; Mario Spatafora; Francesco Ferraù; Luciano Frontini; Alessandra Bearz; Lazzaro Repetto; Cesare Gridelli; Emiddio Barletta; Maria Luisa Barzelloni; Rosario Vincenzo Iaffaioli; Ermelinda De Maio; Massimo Di Maio; Gianfranco De Feo; Giuseppe Sigoriello; Paolo Chiodini; Angela Cioffi; Vincenzo Guardasole; Valentina Angelini; Antonio Rossi; Domenico Bilancia; Domenico Germano; Alfredo Lamberti; Vittorio Pontillo; Luigi Brancaccio; Francesco Renda; Francesco Romano; Gabriella Esani; Anna Gambaro; Orazio Vinante; Giuseppe Azzarello; Maurizia Clerici; Roberto Bollina; Paolo Belloni; Mirella Sannicolò; Libero Ciuffreda; Giuseppe Parello; Mary Cabiddu; Cosimo Sacco; Angela Sibau; Gianfranco Porcile; Federico Castiglione; Oliviero Ostellino; Silvio Monfardini; Micaela Stefani; Giorgio Scagliotti; Giovanni Selvaggi; Filippo De Marinis; Olga Martelli; Giampietro Gasparini; Alessandro Morabito; Domenico Gattuso; Giuseppe Colucci; Domenico Galetta; Francesco Giotta; Vittorio Gebbia; Nicola Borsellino; Antonio Testa; Emilia Malaponte; Matteo A Capuano; Michele Angiolillo; Francesco Sollitto; Umberto Tirelli; Simona Spazzapan; Vincenzo Adamo; Giuseppe Altavilla; Antonio Scimone; Maria Raffaella Hopps; Francesco Tartamella; Giovanni Pietro Ianniello; Vincenza Tinessa; Giuseppe Failla; Roberto Bordonaro; Nicola Gebbia; Maria Rosaria Valerio; Modesto D'Aprile; Enzo Veltri; Maurizio Tonato; Samir Darwish; Sante Romito; Francesco Carrozza; Sandro Barni; Antonio Ardizzoia; Giuliana Mara Corradini; Gianfranco Pavia; Mario Belli; Giuseppe Colantuoni; Enzo Galligioni; Orazio Caffo; Roberto Labianca; Antonello Quadri; Enrico Cortesi; Giuliana D'Auria; Sergio Fava; Anna Calcagno; Gino Luporini; M Cristina Locatelli; Francesco Di Costanzo; Silvia Gasperoni; Luciano Isa; Paola Candido; Fernando Gaion; Giovanni Palazzolo; Giuseppe Nettis; Anselmo Annamaria; Massimo Rinaldi; Massimo Lopez; Raffaella Felletti; Giorgio Bernabò Di Negro; Nestore Rossi; Antonio Calandriello; Luigi Maiorino; Rodolfo Mattioli; Alfredo Celano; Stefania Schiavon; Alfonso Illiano; Carlo Alberto Raucci; Michele Caruso; Paolo Foa; Giuseppe Tonini; Carlo Curcio; Marina Cazzaniga Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman Journal: Breast Cancer Res Treat Date: 2006-05-17 Impact factor: 4.872
Authors: Corey J Langer; Judith Manola; Patricia Bernardo; John W Kugler; Philip Bonomi; David Cella; David H Johnson Journal: J Natl Cancer Inst Date: 2002-02-06 Impact factor: 13.506
Authors: Michelle Shayne; Eva Culakova; Marek S Poniewierski; Debra Wolff; David C Dale; Jeffrey Crawford; Gary H Lyman Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Hyman B Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer Journal: N Engl J Med Date: 2009-05-14 Impact factor: 91.245
Authors: Michelle Shayne; Eva Culakova; Debra Wolff; Marek S Poniewierski; David C Dale; Jeffrey Crawford; Gary H Lyman Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Lindsay L Peterson; Arti Hurria; Tao Feng; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Ilya Glezerman; Vani Katheria; Laura Zavala; David D Smith; Can-Lan Sun; William P Tew Journal: J Geriatr Oncol Date: 2016-11-14 Impact factor: 3.599
Authors: J Feliu; V Heredia-Soto; R Gironés; B Jiménez-Munarriz; J Saldaña; C Guillén-Ponce; M J Molina-Garrido Journal: Clin Transl Oncol Date: 2019-06-25 Impact factor: 3.405
Authors: Ajeet Gajra; Tyler J Zemla; Aminah Jatoi; Josephine L Feliciano; Melisa L Wong; Hongbin Chen; Ronald Maggiore; Ryan P McMurray; Arti Hurria; Hyman B Muss; Harvey J Cohen; Jacqueline Lafky; Martin J Edelman; Rogerio Lilenbaum; Jennifer G Le-Rademacher Journal: J Thorac Oncol Date: 2018-03-30 Impact factor: 15.609
Authors: Michael R Migden; Nikhil I Khushalani; Anne Lynn S Chang; Karl D Lewis; Chrysalyne D Schmults; Leonel Hernandez-Aya; Friedegund Meier; Dirk Schadendorf; Alexander Guminski; Axel Hauschild; Deborah J Wong; Gregory A Daniels; Carola Berking; Vladimir Jankovic; Elizabeth Stankevich; Jocelyn Booth; Siyu Li; David M Weinreich; George D Yancopoulos; Israel Lowy; Matthew G Fury; Danny Rischin Journal: Lancet Oncol Date: 2020-01-14 Impact factor: 41.316
Authors: Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile Journal: J Clin Oncol Date: 2021-05-27 Impact factor: 44.544